Lung Cancer

stage 4 alk :: Article Creator Your Guide To Genetic Mutations In Lung Cancer Gene mutations associated with non-small cell lung cancer include EGFR, HER2, and more. Lung cancer mutations can determine your options for testing and treatment. Genes are the instructions that inform how your body functions. They tell your cells which proteins to make. Proteins control how quickly cells grow, divide, and survive. Sometimes genes change. This may happen before a person is born or later in life. Gene changes are called mutations, and they can affect certain functions in the body. Gene mutations can prevent your DNA from repairing itself and can also cause cells to grow uncontrollably or live for too long. Eventually, these extra cells can form tumors, which is how cancer starts. Certain gene mutations are linked to non-small cell lung cancer (NSCLC). Having one of these mutations could affect the type of treatment a doctor reco

terminal lung cancer life expectancy :: Article Creator A New Era In Small Cell Lung Cancer Treatment Dr. Debu Tripathy, editor-in-chief of CURE magazine, discusses the advancements made in small cell lung cancer. Dr. Debu Tripathy, editor-in-chief of CURE magazine Although advancements in treatments for small cell lung cancer (SCLC) are scarce for this aggressive cancer type, recent regulatory developments and trial results indicate that we are on the precipice of a new era for patients and providers alike. We put a spotlight on these big steps forward and discuss what they mean for the future of SCLC treatment in this seasonal issue of CURE. "The limited options of treatment for patients with small cell lung cancer is the reality that we all confront — but that is not for lack of trying," said Dr. Taofeek K. Owonikoko, executive director of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer C

spindle cell sarcoma :: Article Creator Elraglusib Granted FDA Orphan Drug Status In Soft Tissue Sarcoma The FDA granted orphan drug designation for elraglusib, a novel drug for treating advanced soft tissue sarcoma. This article first appeared with Targeted Oncology™. An orphan drug designation (ODD) was granted by the FDA to elraglusib for the treatment of patients with soft tissue sarcoma (STS).1 Currently, a phase 2, open-label, 2-strata trial is evaluating the combination of elraglusib with gemcitabine and docetaxel in patients 10 years or older with unresectable or metastatic STS or bone sarcomas.2 In this study, investigators are evaluating the primary end point of disease control rate and the secondary end point of progression-free survival (PFS). Daniel Schmitt, MBAImage Credit: Actuate Therapeutics "We are pleased to receive the ODD from the FDA, which underscores elraglusib's potential to address the sig

t2 n1 m0 :: Article Creator

siu pulmonology :: Article Creator Respiratory Syncytial Virus Vaccination In Older Adults This website is using a security service to protect itself from online attacks. The action you just performed triggered the security solution. There are several actions that could trigger this block including submitting a certain word or phrase, a SQL command or malformed data.

stage 3 mesothelioma :: Article Creator What To Know About Peritoneal Mesothelioma Peritoneal mesothelioma is a cancer that develops in the membrane that lines the abdomen and its organs, known as the peritoneum. Asbestos exposure is its most common risk factor. Peritoneal mesothelioma is a type of cancer that currently has no cure. Still, a combination of treatments, including surgery and palliative care, can help manage the condition, improve a person's outlook, and enhance a person's quality of life. This article will discuss peritoneal mesothelioma, including its symptoms, risk factors, causes, diagnosis, and treatment. Peritoneal mesothelioma is the second most common type of mesothelioma, and it involves the peritoneum. The peritoneum is a membrane that surrounds the organs in the abdomen, such as the intestines and the liver. Generally, though, it is a rare type of cancer. Getting an early dia

best treatment for small cell lung cancer :: Article Creator A New Era In Small Cell Lung Cancer Treatment Dr. Debu Tripathy, editor-in-chief of CURE magazine, discusses the advancements made in small cell lung cancer. Dr. Debu Tripathy, editor-in-chief of CURE magazine Although advancements in treatments for small cell lung cancer (SCLC) are scarce for this aggressive cancer type, recent regulatory developments and trial results indicate that we are on the precipice of a new era for patients and providers alike. We put a spotlight on these big steps forward and discuss what they mean for the future of SCLC treatment in this seasonal issue of CURE. "The limited options of treatment for patients with small cell lung cancer is the reality that we all confront — but that is not for lack of trying," said Dr. Taofeek K. Owonikoko, executive director of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Can

metastatic breast cancer survival rate :: Article Creator BriaCell Reports Positive Overall Survival (OS) In Metastatic Breast Cancer Median overall survival of 15.6 months in Phase 2 Bria-IMT™ study patients treated in combination with immune checkpoint inhibitor OS of 15.6 months compares favorably with 6.7-9.3 months reported for similar patients in the literature Ongoing Phase 3 study investigating Bria-IMT™ in similar metastatic breast cancer population No drug related discontinuations to date PHILADELPHIA and VANCOUVER, British Columbia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce positive overall survival data of its Phase 2 clinical study of Bria-IMT™ in combination with an immune check point inhibitor (CPI) in